Gilead Sciences Balance Sheet Health
Financial Health criteria checks 4/6
Gilead Sciences has a total shareholder equity of $21.1B and total debt of $25.2B, which brings its debt-to-equity ratio to 119.7%. Its total assets and total liabilities are $62.3B and $41.2B respectively. Gilead Sciences's EBIT is $9.8B making its interest coverage ratio 10.7. It has cash and short-term investments of $7.1B.
Key information
119.7%
Debt to equity ratio
US$25.25b
Debt
| Interest coverage ratio | 10.7x |
| Cash | US$7.10b |
| Equity | US$21.09b |
| Total liabilities | US$41.24b |
| Total assets | US$62.34b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 000935700's short term assets ($14.3B) exceed its short term liabilities ($14.0B).
Long Term Liabilities: 000935700's short term assets ($14.3B) do not cover its long term liabilities ($27.3B).
Debt to Equity History and Analysis
Debt Level: 000935700's net debt to equity ratio (86%) is considered high.
Reducing Debt: 000935700's debt to equity ratio has reduced from 133.7% to 119.7% over the past 5 years.
Debt Coverage: 000935700's debt is well covered by operating cash flow (37.7%).
Interest Coverage: 000935700's interest payments on its debt are well covered by EBIT (10.7x coverage).